Fractyl Laboratories

OverviewSuggest Edit

Fractyl Laboratories is a company developing solutions for the treatment of chronic diseases. It is engaged in the development of a minimally invasive procedural therapy that can reverse metabolic diseases. In addition, it offers Revita DMR technology for patients with type 2 diabetes
TypePrivate
Founded2010
HQLexington, MA, US
Websitefractyl.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2021)60
Cybersecurity ratingBMore

Key People/Management at Fractyl Laboratories

Brian Dovey

Brian Dovey

Director
Allan Will

Allan Will

Chairman
Jay Caplan

Jay Caplan

Co-Founder and President
Chris Gabrieli

Chris Gabrieli

Director
Lisa Davidson

Lisa Davidson

Chief Financial Officer
Len Rosberg

Len Rosberg

Vice President of Manufacturing
Show more

Fractyl Laboratories Office Locations

Fractyl Laboratories has an office in Lexington
Lexington, MA, US (HQ)
17 Hartwell Avenue
Show all (1)

Fractyl Laboratories Financials and Metrics

Summary Metrics

Founding Date

2010

Fractyl Laboratories total Funding

$190.1 m

Fractyl Laboratories latest funding size

$55 m

Time since last funding

10 months ago

Fractyl Laboratories investors

Fractyl Laboratories's latest funding round in August 2020 was reported to be $55 m. In total, Fractyl Laboratories has raised $190.1 m
Show all financial metrics

Fractyl Laboratories Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Fractyl Laboratories Online and Social Media Presence

Embed Graph

Fractyl Laboratories News and Updates

Taiwania Capital leads $55m Series E round in Fractyl Laboratories

The round was joined by existing investors including Bessemer Venture Partners, General Catalyst, Domain Associates and Mithril Capital Management. The post Taiwania Capital leads $55m Series E round in Fractyl Laboratories appeared first on DealStreetAsia.

Fractyl Laboratories Blogs

Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes

LEXINGTON, Mass., April 27, 2021 – Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device …

Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita® DMR for Type 2 Diabetes

– Landmark REVITA-T2Di study will assess potential of outpatient Revita DMR treatment to eliminate need for daily insulin – LEXINGTON, Mass., March 22, 2021 — Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the m…

Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated

LEXINGTON, Mass., February 1, 2021 — Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced the publication of clinical results from the investigator-initiated INSPIRE clinical trial c…

Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes

LEXINGTON, Mass., August 6, 2020 – Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced a first close of $55 million in a Series E financing. The financing was led by new investor Ta…

Fractyl Announces FDA IDE Approval to Begin Pivotal Study of Revita DMR for Insulin-Treated Patients with Type 2 Diabetes

LEXINGTON, Mass., June 3, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) to begin a pivotal study of RevitaⓇ DMR in type 2 diabetes (T2D) patients treated …

Fractyl Announces New Clinical Data on the Mechanism of Revita DMR in Type 2 Diabetes

LEXINGTON, Mass., March 30, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced clinical data that elucidate the mechanisms behind the beneficial effects and significant improvements in metabolic disease parameters for type 2 diabetes patients after one Revita® duodenal mucosal resurfacing (D…
Show more

Fractyl Laboratories Frequently Asked Questions

  • When was Fractyl Laboratories founded?

    Fractyl Laboratories was founded in 2010.

  • Who are Fractyl Laboratories key executives?

    Fractyl Laboratories's key executives are Brian Dovey, Allan Will and Jay Caplan.

  • How many employees does Fractyl Laboratories have?

    Fractyl Laboratories has 60 employees.

  • Who are Fractyl Laboratories competitors?

    Competitors of Fractyl Laboratories include Auxulin Pharmaceuticals, Metavention and Viatris.

  • Where is Fractyl Laboratories headquarters?

    Fractyl Laboratories headquarters is located at 17 Hartwell Avenue, Lexington.

  • Where are Fractyl Laboratories offices?

    Fractyl Laboratories has an office in Lexington.

  • How many offices does Fractyl Laboratories have?

    Fractyl Laboratories has 1 office.